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A recent trial of drugs for invasive aspergillosis was used as a background for discussing critical features in
the design of antifungal trials. The study under discussion allowed stopping either drug without classifying
the patient as having treatment failure, so the trial should be understood as a comparison of 2 treatment
strategies, not just 2 drugs. Although the study was a noninferiority trial, the outcome permitted a claim of
superiority. Use of the category of “probable” in addition to “proven” aspergillosis permitted inclusion of
patients for whom the diagnosis was less certain but who were still early enough in the disease progression
to respond to therapy. Different opinions still exist about some of the criteria for the diagnosis of “probable”
aspergillosis. A blinded data review committee was helpful in evaluating efficacy in this unblinded trial but
had limited value in assessing toxicity. An understanding of these features of design of antifungal drug trials
is important in applying the results to clinical practice.
Previous publications about drug efficacy in invasive
aspergillosis have been clinical descriptions or, in the
one prospective clinical trial, a comparison of 2 doses
of the same drug [1]. Definitions of invasive aspergil-
losis in prior drug studies have been varied and often
imprecise. The recent multicenter comparative study of
voriconazole versus amphotericin B for the treatment
of invasive aspergillosis [2] used detailed descriptions
for case definitions and presented an opportunity to
discuss the study entry criteria, end points, the selection
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of comparators, the use of data review committees
(DRCs), statistical analysis, and population pharmaco-
kinetics.
STUDIES THAT PERMIT A CHANGE
FROM THE RANDOMIZED DRUG
The voriconazole study permitted a change from the
randomized drug to any other licensed antifungal drug,
without requiring that the patient be classified as having
had treatment failure of the randomized drug. This
strategy is similar to the “success with modification”
used previously in studies by the National Cancer In-
stitute of empirical antibacterial therapy in neutropenic
patients. The Immunocompromised Host Society re-
jected the success-with-modification design after a con-
sensus meeting. Viscoli [3] distinguished between clin-
ical trials that were “pragmatic” and those that were
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“explanatory.” According to Viscoli’s definition, pragmatic tri-
als such as the voriconazole trial or the success-with-modifi-
cation trials are suitable to evaluate a management strategy and
can apply to clinical practice but cannot give a quantitative
estimate of the efficacy of a new drug compared with that of
an old drug. Measurement of mortality and detailed definitions
of permissible therapeutic modifications are essential compo-
nents of pragmatic clinical trials. The case report form should
provide a complete explanation of the reasons for any change
in therapy. As discussed below, a blinded DRC can validate
whether the therapeutic modifications were permissible within
the protocol.
SELECTION OF COMPARATOR DRUGS
The investigators and the sponsor of the trial of voriconazole
in treating invasive aspergillosis selected amphotericin B deox-
ycholate as the initial comparator drug because it was the only
licensed drug for the initial treatment of invasive aspergillosis
in the United States. The toxicity of amphotericin B deoxy-
cholate led to a change to another licensed antifungal drug for
107 of 133 patients in the comparator arm of the trial. Although
amphotericin B deoxycholate has been accepted for many years
as the standard for primary treatment of invasive aspergillosis,
the advent of new lipid-based formulations of amphotericin B
and the echinocandins raised the question of whether it is still
appropriate to use amphotericin B deoxycholate as the com-
parator in all new antifungal trials. The answer hinges on
whether a different formulation of an approved drug, such as
a lipid amphotericin B formulation, can be accepted as a com-
parator when it is not approved by the US Food and Drug
Administration (FDA) as initial therapy for invasive aspergil-
losis. Accepting an unlicensed formulation as the comparator
would be tantamount to approving the formulation without a
clinical trial, creating an unacceptable precedent. At the meeting
of the FDA Advisory Committee on Caspofungin, the FDA
indicated willingness to consider alternative comparators at the
protocol design stage, as long as investigators and sponsors
provided further supporting data on the efficacy of comparators
unlicensed for that indication. The FDA also stated that it
would consider the results of a clinical trial designed to show
the superiority (not equivalence) of a new drug compared with
an unlicensed drug or formulation. This is based on the fact
that a superiority trial that shows that a particular drug is indeed
superior to another proves that the test drug must be better
than placebo. This is a high hurdle for a new drug, however,
and investigators and sponsors rarely choose this option. There
is no FDA requirement that a new drug be superior to already
licensed drugs in either efficacy or toxicity, although there are
marketing and clinical reasons for wanting such an advantage.
NONINFERIORITY TRIALS
The voriconazole aspergillosis study was a noninferiority trial,
like most trials of new antifungal drugs, with a noninferiority
margin (delta) of 20%. That is, the study hoped to reject the
hypothesis that the voriconazole arm experienced a 20% worse
outcome than the amphotericin B deoxycholate arm. It is im-
portant to understand the difference between this kind of a
design and a superiority trial. In a superiority trial, the study
is designed to determine whether a particular drug is superior
to another. Failure to establish superiority of one drug over the
other does not definitely establish that they are equivalent, be-
cause the sample size of the trial may be too small to establish
noninferiority. A potentially useful equivalent drug could be
discarded as a result of a failed superiority trial. In a nonin-
feriority trial, one drug is assumed to be inferior to another
drug and the study is designed to establish whether 2 drugs
are equally effective. The typical criterion for noninferiority
between drugs is to establish limits of a confidence interval for
the difference in efficacy between drugs. If the confidence in-
terval lies within prespecified limits, the drugs are considered
comparable with respect to efficacy. Without prior knowledge
that the older drug is effective, one cannot conclude from a
noninferiority trial that either drug is better than nothing at
all. Although a noninferiority trial is not designed to test su-
periority, that conclusion can be inferred if the lower boundary
of the confidence interval around the difference between the
response rates of the test drug minus the comparator drug is
10 [4].
Once the older, comparator drug has been shown to be su-
perior to no treatment, the next consideration in selecting a
noninferiority margin is the clinical judgment of what is an
acceptable loss of efficacy relative to current therapies for that
particular disease. This must also take into account that se-
lecting a smaller noninferiority margin may increase the sample
size for a clinical trial. For severe diseases, selection of a rela-
tively small delta is preferable, to ensure as little loss of efficacy
as possible relative to the control agent. This may not be pos-
sible if the disease is relatively uncommon. In some cases, the
number of patients required to allow the trial to have adequate
statistical power may be larger than the number of patients
who have the illness in question. However, the noninferiority
margin cannot be greater than the benefit of drug therapy over
placebo. For instance, if the benefit of drug therapy over placebo
is 15%, then a noninferiority margin of 10% would be appro-
priate whereas a noninferiority margin of 20% would not.
In the trial of voriconazole to treat invasive aspergillosis, the
noninferiority margin selected before initiation of the trial was
20% [2]. This means that investigators could conclude that the
voriconazole arm was not inferior to the amphotericin B arm
if the lower bound of the 95% confidence interval around the
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difference in the efficacy of voriconazole minus the difference
in the control regimen was not more negative than20%. The
noninferiority margin of 20% was justified by historical data
indicating that the efficacy of amphotericin B in this population
was well above 20%. Because the lower bound of the 95%
confidence interval around the difference between the 2 drugs
(voriconazole minus amphotericin B followed by other licensed
therapy) for the primary end point was 10, it was possible to
conclude that the voriconazole arm was statistically superior
to the amphotericin B deoxycholate arm.
ENTRY CRITERIA
Efforts to reach a consensus about entry into a therapeutic trial
for deep mycoses, including aspergillosis, in immunocom-
promised patients have resulted in a publication [5]. To date,
these criteria have not been used in a clinical trial. Although
there are some differences between the entry criteria in the
voriconazole trial and the published consensus, the 2 sets of
diagnostic criteria do agree in including the important element
of combining the host’s risk factors with the radiological and
laboratory findings.
USE OF THE HALO SIGN IN DIAGNOSIS OF
INVASIVE ASPERGILLOSIS
In prolonged neutropenia, investigators have advocated the
identification of a halo sign on thoracic CT as a sensitive, early
sign of invasive pulmonary aspergillosis [6]. The specificity of
the halo sign is less clear. There is no consensus about the
precise radiological definition of the halo sign so that one would
expect variability between centers in detecting this finding. In
the voriconazole randomized trial of invasive aspergillosis, the
DRC radiologists could not confirm the presence of a halo sign
for 57 of 95 patients. The major problem in confirming a
diagnosis appeared to be the lack of a uniform definition in
hospital radiology departments. Lack of appropriate documen-
tation may also have been a significant contributing factor. It
is possible that the DRC did not receive the best CT scans to
demonstrate the halo. Because a uniform definition was used
among the radiologists in the voriconazole DRC, there was
complete agreement in the radiological assessment of response
between the United States and European DRCs in 180% of
cases. The therapeutic outcomes of patients for whom the di-
agnosis of invasive aspergillosis was rejected by the DRC ra-
diologists were the same as outcomes for those whose diagnosis
was accepted by the DRC, suggesting, but not confirming, a
similar etiology in both groups. If this is true, then the sensi-
tivity of the halo sign may be less than the reported figure of
84% (16/19 proven cases) [6].
A uniform definition of the halo sign is needed and should
include radiological criteria, a description of the patient pop-
ulation to which the sign applies, estimates of the sensitivity
and specificity of the sign, and a description of other diseases
in this same population that can produce a halo sign.
DRCS
Blinded DRCs examine radiographs and case report forms that
have been purged of details that may disclose the identity of
the randomized drug. The trial of voriconazole to treat asper-
gillosis [2] included both US and European DRCs composed
of clinicians and radiologists who confirmed study eligibility
and response to therapy. As exemplified in the voriconazole
trial, blinded DRCs can play a valuable role in the successful
conduct of randomized multicenter trials by identifying a need
for additional data about individual patients, confirming eli-
gibility for study entry, validating outcome, and providing a
central place for resolving technical issues as they arise. In
addition, patients with unusual outcomes, such as unexpected
treatment failure, are identified and given special scrutiny.
Blinded DRCs also ensure that rules are applied uniformly in
both arms of the trial. This is particularly important in complex
trials that include some inexperienced investigators.
Blinded DRCs are, however, not without some disadvantages.
Because of data purging, DRC members frequently have an
incomplete data set to review. The DRC cannot adequately
assess drug toxicity because laboratory values and narrative
comments that might provide a clue to the drug identity have
been removed. Although the DRC can review toxicity once the
study is completed and the blind has been broken, toxicity data
not already reported to the company are difficult to retrieve
after such a long time lag. A blinded DRC may reverse the
investigator’s claim of efficacy simply because there is insuffi-
cient documentation provided to support it. When the DRC
deletes cases from the modified intent-to-treat analysis, the
reduced patient numbers decrease the power of the study and
may limit the opportunity to draw valid conclusions. The FDA
routinely examines analyses of both the intent-to-treat popu-
lation and the modified intent-to-treat population to see
whether the results are in accordance. Studies that have a large
number of patients excluded from the modified intent-to-treat
analysis might show dissimilar results from the intent-to-treat
population because of some bias in the DRC exclusion process.
When 11 DRC is used, evidence must be provided that the
results are in agreement. In the trial of voriconazole to treat
aspergillosis, comparison of the results of the European and
US DRC evaluations of the same case report forms and radi-
ological studies found 190% agreement as to outcome as suc-
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cess or failure, indicating that both DRCs were applying the
same criteria.
ADDITION OF NARRATIVES TO CASE REPORT
FORMS
Improvements in the design of case report forms would en-
hance the work of blinded DRCs. Specifically, the addition of
narrative patient summaries, written by the investigator, would
greatly improve the DRC’s understanding of why investigators
made certain clinical decisions. Experience from the DRCs of
the trial of voriconazole as empirical antifungal therapy and
the trial of caspofungin as treatment for invasive aspergillosis
showed that asking the investigator to prepare individual pa-
tient summaries can help a blinded DRC to understand more
about the time course and rationale for clinical decisions. The
summaries may also provide valuable information about why
a drug was stopped for lack of efficacy. Improved, more com-
plete check-off boxes on case report forms may also help the
blinded DRC to confirm or disagree that early discontinuation
of therapy for lack of efficacy or toxicity was appropriate.
The caveats to the use of narratives in the case report form
include the necessity for keeping the DRC blinded as to study
drug and the possibility that the study nurses who fill out the
majority of the case report forms may have difficulty writing
a summary that captures all of the major management deci-
sions. The addition of narratives does add considerably to the
workload of the data managers and statisticians. Use of nar-
rative summaries also raises questions on how best to analyze
these additional data.
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